Abbott Laboratories dividend yield – ABBOTT LABORATORIES Delivers Outstanding Total Returns with Growing Prowess in Healthcare and Alluring Dividend Theme.

Trending News ☀️

Abbott Laboratories dividend yield – ABBOTT LABORATORIES ($NYSE:ABT) is a leading healthcare company that has seen tremendous growth over the past few years. The company produces a range of products and services, including diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals. This success is reflected in the comparison of total returns and price returns for ABT stock in the image below from YCharts. Total returns include both changes in the stock price plus dividends and other distributions paid to shareholders. As the image shows, ABT stock has seen far more growth in total returns than in price returns over the past five years. Furthermore, by reinvesting its profits into research and development and expanding into new markets, Abbott Laboratories has been able to stay ahead of the competition in the healthcare sector. This focus on innovation and growth has enabled the company to remain competitive and continue to deliver superior total returns for its shareholders.

Additionally, investors are also reassured by the strength of ABT’s balance sheet, which allows the company to maintain its dividend policy even during periods of economic uncertainty. In summary, ABBOTT LABORATORIES has been able to deliver outstanding total returns with growing prowess in the healthcare sector and an alluring dividend theme. The company’s commitment to innovation and strong balance sheet enables it to continue to perform well and attract both institutional and retail investors alike.

Dividends – Abbott Laboratories dividend yield

Over the last three years, the company has issued annual dividends per share at 1.88 USD- a remarkable achievement for shareholders. On top of that, the dividend yields from 2022 to 2023 are an impressive 1.61%, with an average dividend yield of 1.61%. This has been a powerful incentive for investors, and is a testament to the company’s commitment to shareholder value.

In addition, ABBOTT Laboratories has been investing heavily in research and development, which has helped them stay at the cutting edge of healthcare innovation. The company’s focus on developing new products, services, and technologies has allowed them to remain competitive in the global healthcare industry. Moreover, ABBOTT Laboratories’ commitment to quality healthcare has enabled them to become an industry leader in patient care, providing top-notch products to their customers worldwide. As a result, ABBOTT Laboratories has become a prime example of what can be achieved through strong financial and operational performance.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Abbott Laboratories. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Abbott Laboratories. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…

Key Ratios Snapshot

Some of the financial key ratios for Abbott Laboratories are shown below. More…

Stock Price

At the time of writing, news sentiment was mostly positive. On Tuesday, ABBOTT LABORATORIES stock opened at $108.2 and closed at $107.3, down by 1.2% from prior closing price of 108.5. The company has grown in leaps and bounds over the years, establishing itself as a leader in healthcare. It offers medical products and services that enable people of all ages to live healthy lives. This dividend theme has been a major attraction for investors seeking consistent income. The company’s long-term growth story is further bolstered by its focus on innovation and R&D. It has invested heavily in research to come up with products that meet the changing needs of its customers. This commitment to innovation has resulted in successful launches of several new products, including medicines for cardiovascular diseases, diabetes, and HIV.

In addition, ABBOTT LABORATORIES has been able to expand its presence in new markets such as China and Latin America. The company’s commitment to expanding its global footprint is a testament to its ability to execute on strategy and take advantage of new opportunities. With its focus on innovation and global expansion, the company is sure to continue delivering exceptional value to its shareholders. Live Quote…

Analysis

ABBOTT LABORATORIES is a strong and successful company, as evidenced by GoodWhale’s Star Chart analysis of its wellbeing. The health score of 9/10 reflects ABBOTT LABORATORIES’s cashflows and debt, and its ability to fund future operations and pay off debt. ABBOTT LABORATORIES is considered a ‘gorilla’, meaning that it has achieved consistent growth in revenue and profits due to its strong competitive advantage. Investors who may be interested in such a company include those who seek dividend income, growth opportunities, and a strong return on investment. ABBOTT LABORATORIES’s performance in these areas is high; however, some investors may be hesitant due to its medium scores in asset management. Overall, ABBOTT LABORATORIES’s Star Chart analysis indicates that it is a well-run and successful company, with potential for further growth. Its strong financials, consistent revenue and profit growth, and dividend income make it an attractive option for investors looking for a solid return on their investments. More…

Peers

Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.

– OraSure Technologies Inc ($NASDAQ:OSUR)

OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.

OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.

– Quidel Corp ($NASDAQ:QDEL)

Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.

– Lucira Health Inc ($NASDAQ:LHDX)

Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.

Summary

ABBOTT LABORATORIES is an attractive investment option due to its impressive total returns, impressive growth in healthcare, and attractive dividend payouts. The company has seen a steady increase in share prices recently, with many analysts expecting further growth. In addition, its dividend payouts have been consistently increasing, resulting in higher yields for investors. With its strong presence in the healthcare sector and a strong financial track record, ABBOTT LABORATORIES is an attractive option for investors looking for strong returns.